| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 72237-0101-02 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
| 50881-0010-60 | 50881-0010 | Ruxolitinib | Jakafi | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1 and JAK 2 (Janus Kinase Inhibitor) | Oral | Nov 16, 2011 | In Use | |
| 71779-0115-01 | 71779-0115 | duvelisib | Copiktra | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 00078-0627-51 | 00078-0627 | Everolimus | Afinitor | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Aug 29, 2012 | In Use | |
| 00008-1179-01 | 00008-1179 | Temsirolimus | Torisel | Chemotherapy | Enzyme Inhibitor | mTOR | Intravenous | Jul 1, 2007 | In Use | ||
| 72603-0257-01 | 72603-0257 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2024 | In Use | |
| 51991-0990-28 | 51991-0990 | Everolimus | Everolimus | 2.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 28, 2025 | In Use | |
| 51991-0992-28 | 51991-0992 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 28, 2025 | In Use | |
| 71779-0125-02 | 71779-0125 | duvelisib | Copiktra | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 46014-0296-01 | 46014-0296 | talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct 26, 2018 | In Use | |
| 70377-0010-22 | 70377-0010 | Everolimus | EVEROLIMUS | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2021 | In Use | |
| 00173-0846-08 | 00173-0846 | Dabrafenib | Tafinlar | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Jun 10, 2013 | Aug 31, 2018 | No Longer Used |
| 71332-0006-90 | 71332-0006 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jun 24, 2024 | In Use | |
| 72611-0785-02 | 72611-0785 | Temsirolimus Injection | Temsirolimus | Chemotherapy | Enzyme Inhibitor | mTOR | Intravenous | May 8, 2020 | In Use | ||
| 71334-0100-01 | 71334-0100 | Ivosidenib | Tibsovo | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Jul 20, 2018 | Nov 30, 2024 | No Longer Used |
| 71332-0005-01 | 71332-0005 | Olutasidenib | REZLIDHIA | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Dec 1, 2022 | In Use | |
| 00054-0481-13 | 00054-0481 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Feb 12, 2021 | In Use | |
| 50242-0090-02 | 50242-0090 | Vemurafenib | Zelboraf | 240.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Sep 8, 2015 | In Use | |
| 72237-0102-06 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
| 82950-0001-16 | 82950-0001 | TOVORAFENIB | OJEMDA | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Oral | Apr 30, 2024 | In Use | |
| 70377-0012-11 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
| 72237-0102-02 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
| 00245-0823-04 | 00245-0823 | Everolimus | TORPENZ | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 21, 2025 | In Use | |
| 00078-0594-61 | 00078-0594 | Everolimus | Afinitor | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 9, 2010 | In Use | |
| 00310-0679-60 | 00310-0679 | Olaparib | Lynparza | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 17, 2017 | In Use |
Found 12250 results — Export these results
Home